271 related articles for article (PubMed ID: 31518013)
1. The combination of granulocyte-monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis?
Rodríguez-Lago I; Benítez JM; Sempere L; Sáez-González E; Barreiro-de Acosta M; de Zárate JO; Cabriada JL
J Clin Apher; 2019 Dec; 34(6):680-685. PubMed ID: 31518013
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte-monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis.
Rodríguez-Lago I; Sempere L; Gutiérrez A; Núñez A; Leo Carnerero E; Hinojosa E; Mora M; Cañete F; Mañosa M; Herrera C; Beltrán B; Forés A; Arjona D; Barreiro-de Acosta M; Khorrami S; Aguirre U; Ginard D; Cabriada JL
Scand J Gastroenterol; 2019 Apr; 54(4):459-464. PubMed ID: 30982369
[No Abstract] [Full Text] [Related]
3. Refractory Ulcerative Colitis Improved by Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis.
Nakamura M; Yamamura T; Maeda K; Sawada T; Mizutani Y; Ishikawa E; Ohashi A; Kajikawa G; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Fujishiro M
Intern Med; 2020 Dec; 59(23):3009-3014. PubMed ID: 32727993
[TBL] [Abstract][Full Text] [Related]
4. Selective granulocyte-monocyte apheresis during induction with vedolizumab in moderate-severe ulcerative colitis: Experience in a tertiary hospital.
Suárez Ferrer C; Martin-Arranz E; Martín-Arranz MD
Gastroenterol Hepatol; 2024 Jan; ():. PubMed ID: 38219961
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA and granulocyte-monocyte adsorption apheresis combotherapy after inadequate response to anti-TNF agents in ulcerative colitis.
Sáez-González E; Moret-Tatay I; Bastida G; Aguas M; Iborra M; Nos P; Beltrán B
J Clin Apher; 2024 Feb; 39(1):e22101. PubMed ID: 38054256
[TBL] [Abstract][Full Text] [Related]
6. Dose-intensified granulocyte-monocyte apheresis in therapy refractory ulcerative colitis.
Schultheiß C; Weischenberg R; Herrmann A; Haller B; Schmid RM; Reindl W; Huber W
Artif Organs; 2015 Feb; 39(2):187-92. PubMed ID: 24981894
[TBL] [Abstract][Full Text] [Related]
7. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.
Iborra M; Beltrán B; Maroto N; Navarro-Cortés P; Boscá-Watts M; Ferrer-Bradley I; García-Morales N; Sáez-González E; Hinojosa J; Mínguez M; Nos P
Gastroenterol Hepatol; 2018 Nov; 41(9):535-543. PubMed ID: 30031573
[TBL] [Abstract][Full Text] [Related]
8. Pyoderma gangrenosum in an ulcerative colitis patient during treatment with vedolizumab responded favorably to adsorptive granulocyte and monocyte apheresis.
Shibuya T; Haga K; Saeki M; Haraikawa M; Tsuchihashi H; Okahara K; Nomura O; Fukushima H; Murakami T; Ishikawa D; Ikeda S; Nagahara A
J Clin Apher; 2020 Sep; 35(5):488-492. PubMed ID: 32767842
[TBL] [Abstract][Full Text] [Related]
9. Effect and safety of granulocyte-monocyte adsorption apheresis for patients with ulcerative colitis positive for cytomegalovirus in comparison with immunosuppressants.
Yoshino T; Nakase H; Matsuura M; Matsumura K; Honzawa Y; Fukuchi T; Watanabe K; Murano M; Tsujikawa T; Fukunaga K; Matsumoto T; Chiba T
Digestion; 2011; 84(1):3-9. PubMed ID: 21311190
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of granulocyte and monocyte adsorption apheresis in paediatric inflammatory bowel disease: a prospective pilot study.
Martín de Carpi J; Vilar P; Prieto G; García Novo MD; Ribes C; Varea V
J Pediatr Gastroenterol Nutr; 2008 Apr; 46(4):386-91. PubMed ID: 18367949
[TBL] [Abstract][Full Text] [Related]
11. Fecal calprotectin is a useful biomarker for predicting the clinical outcome of granulocyte and monocyte adsorptive apheresis in ulcerative colitis patients: a prospective observation study.
Ueno N; Sugiyama Y; Kobayashi Y; Murakami Y; Iwama T; Sasaki T; Kunogi T; Takahashi K; Tanaka K; Ando K; Kashima S; Inaba Y; Moriichi K; Tanabe H; Taruishi M; Saitoh Y; Okumura T; Fujiya M
BMC Gastroenterol; 2021 Aug; 21(1):316. PubMed ID: 34362299
[TBL] [Abstract][Full Text] [Related]
12. Combination of granulocyte-monocyte apheresis and ustekinumab: Multicentre and retrospective study.
Rodríguez-Lago I; Herrera-deGuise C; Boscá-Watts M; Rodríguez C; Leo-Carnerero E; Íñiguez MC; Cañete F; Chacón S; Cuarán C; Elorza A; Guerra-Del-Río E; Iglesias E; Sánchez D; Barreiro-de Acosta M; Ginard D; Cabriada JL
Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38710466
[TBL] [Abstract][Full Text] [Related]
13. Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease in special situations: a multicentre cohort study.
Motoya S; Tanaka H; Shibuya T; Osada T; Yamamoto T; Hongo H; Mizuno C; Saito D; Aoyama N; Kobayashi T; Ito H; Tanida S; Nojima M; Kokuma S; Hosoi E
BMC Gastroenterol; 2019 Nov; 19(1):196. PubMed ID: 31752695
[TBL] [Abstract][Full Text] [Related]
14. Granulocyte-Monocyte Apheresis as an Adjuvant Therapy to Anti-Tumor Necrosis Factor Drugs for Ulcerative Colitis.
Rodríguez-Lago I; Gómez-Irwin L; Fernández E; Higuera R; Cabriada JL
Ther Apher Dial; 2017 Feb; 21(1):26-30. PubMed ID: 28078747
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with the outcomes in ulcerative colitis patients undergoing granulocyte and monocyte adsorptive apheresis as remission induction therapy: A multicenter cohort study.
Ishiguro Y; Ohmori T; Umemura K; Iizuka M
Ther Apher Dial; 2021 Aug; 25(4):502-512. PubMed ID: 33029920
[TBL] [Abstract][Full Text] [Related]
16. Ulcerative colitis with hepatitis B virus infection treated successfully by granulocyte monocyte apheresis.
Saito H; Hanafusa N; Kishikawa J; Noiri E; Sunami E; Ishihara S; Watanabe T; Nangaku M
J Clin Apher; 2016 Dec; 31(6):584-586. PubMed ID: 26876484
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Adsorptive Granulocyte and Monocyte Apheresis in Elderly and Pregnant Patients With Ulcerative Colitis.
Yanagisawa K; Murakami M; Kondo Y; Oguma S; Kobayashi S; Miyasaka H; Shinohara T; Tomori A; Nakano Y; Furuhata S; Ikezoe M
Ther Apher Dial; 2019 Jun; 23(3):217-223. PubMed ID: 31025815
[TBL] [Abstract][Full Text] [Related]
18. Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial.
Domènech E; Panés J; Hinojosa J; Annese V; Magro F; Sturniolo GC; Bossa F; Fernández F; González-Conde B; García-Sánchez V; Dignass A; Herrera JM; Cabriada JL; Guardiola J; Vecchi M; Portela F; Ginard D;
J Crohns Colitis; 2018 May; 12(6):687-694. PubMed ID: 29490024
[TBL] [Abstract][Full Text] [Related]
19. Granulocyte-monocyte adsorptive apheresis in pediatric inflammatory bowel disease: results, practical issues, safety, and future perspectives.
Ruuska T; Wewer V; Lindgren F; Malmborg P; Lindquist M; Marthinsen L; Browaldh L; Casswall T; Kalliomäki M; Grönlund J
Inflamm Bowel Dis; 2009 Jul; 15(7):1049-54. PubMed ID: 19137602
[TBL] [Abstract][Full Text] [Related]
20. Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA.
Yokoyama Y; Kawai M; Fukunaga K; Kamikozuru K; Nagase K; Nogami K; Kono T; Ohda Y; Iimuro M; Hida N; Nakamura S; Miwa H; Matsumoto T
BMC Gastroenterol; 2013 Feb; 13():27. PubMed ID: 23399416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
